ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
P/E ratio for ImmunoGen, Inc. (IMGN)
P/E ratio as of 2022: -5.64
According to ImmunoGen, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.64. At the end of 2021 the company had a P/E ratio of -8.44.
P/E ratio history for ImmunoGen, Inc. from 1988 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -5.64 |
| 2021 | -8.44 |
| 2020 | -17.04 |
| 2019 | -6.21 |
| 2018 | -4.00 |
| 2017 | -6.55 |
| 2016 | -1.13 |
| 2015 | -1.86 |
| 2014 | -20.37 |
| 2013 | -14.19 |
| 2012 | -19.85 |
| 2011 | -17.54 |
| 2010 | -14.42 |
| 2009 | -10.71 |
| 2008 | -13.78 |
| 2007 | -4.11 |
| 2006 | -12.21 |
| 2005 | -7.23 |
| 2004 | -21.61 |
| 2003 | -41.70 |
| 2002 | -8.96 |
| 2001 | -6.39 |
| 2000 | -47.97 |
| 1999 | -1498.65 |
| 1998 | -14.38 |
| 1997 | -5.57 |
| 1996 | -3.10 |
| 1995 | -3.22 |
| 1994 | -2.45 |
| 1993 | -2.03 |
| 1992 | -3.69 |
| 1991 | -7.75 |
| 1990 | -9.96 |
| 1989 | -8.56 |
| 1988 | -2.83 |